<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00090870</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000378049</org_study_id>
    <secondary_id>MUSC-100614</secondary_id>
    <secondary_id>CELGENE-MUSC-100614</secondary_id>
    <secondary_id>MUSC-HR-10423</secondary_id>
    <nct_id>NCT00090870</nct_id>
  </id_info>
  <brief_title>PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer</brief_title>
  <official_title>A Phase II Study Of Peg-Intron, GM-CSF And Thalidomide In Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: PEG-interferon alfa-2b may interfere with the growth of tumor cells.
      Colony-stimulating factors such as sargramostim may increase the number of immune cells found
      in bone marrow or peripheral blood. Thalidomide may stop the growth of cancer by stopping
      blood flow to the tumor. Combining PEG-interferon alfa-2b with sargramostim and thalidomide
      may kill more tumor cells.

      PURPOSE: This phase II trial is studying how well giving PEG-interferon alfa-2b together with
      sargramostim and thalidomide works in treating patients with metastatic kidney cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the response to PEG-interferon alfa-2b, sargramostim (GM-CSF), and thalidomide
           in patients with metastatic renal cell carcinoma.

      Secondary

        -  Determine duration of response in patients treated with this regimen.

        -  Determine the tolerance to and toxicity of this regimen in these patients.

        -  Determine the median and progression-free survival of patients treated with this
           regimen.

      OUTLINE: Patients receive PEG-interferon alfa-2b subcutaneously (SC) on days 1 and 8,
      sargramostim (GM-CSF) SC on days 1-10, and oral thalidomide once daily on days 1-21. Courses
      repeat every 21 days in the absence of disease progression or unacceptable toxicity.

      Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then
      annually thereafter.

      PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Pharmaceutical collaborator pulled funding.
  </why_stopped>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>while on study, every 4 cycles; while off study, every 3 months for 1 year, then every 6 month for 2 years, then every year</time_frame>
    <description>To define the response rate in metastatic renal cell carcinoma patients receiving Peg-Intron, GM-CSF and thalidomide</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>time from registration to the time of progressive disease among patients who achieve at least a partial response to treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Adverse Events Assessed by NCI CTC Version 2</measure>
    <time_frame>From the first day of treatment until the end of treatment visit, an average of 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>From registration until diease progression or death, whichever comes first.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Kidney Cancer</condition>
  <arm_group>
    <arm_group_label>PEG-Intron, BM-CSF and thalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PEG-interferon alfa-2b</intervention_name>
    <description>Peg-Intron 1ug/kg Subcutaneous on day 1 and day 8 of each cycle. Each cycle is 21 days.</description>
    <arm_group_label>PEG-Intron, BM-CSF and thalidomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GM-CSF</intervention_name>
    <description>GM-CSF 250 ug/m2 subcutaneously daily from days 1-10 or each 21 day Peg-Intron cycle</description>
    <arm_group_label>PEG-Intron, BM-CSF and thalidomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
    <description>200mg daily by mouth</description>
    <arm_group_label>PEG-Intron, BM-CSF and thalidomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed renal cell carcinoma

               -  Metastatic disease

          -  Measurable disease

               -  Unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm
                  by spiral CT scan or MRI

                    -  Histologic confirmation required if measurable disease is confined to a
                       solitary lesion

               -  The following are not considered measurable disease:

                    -  Bone disease only

                    -  Pleural or peritoneal metastases

                    -  CNS lesions

                    -  Irradiated lesions unless disease progression was documented after prior
                       radiotherapy

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Granulocyte count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

        Hepatic

          -  Bilirubin ≤ 1.5 mg/dL

          -  No decompensated liver disease

        Renal

          -  Creatinine ≤ 2.0 mg/dL

        Immunologic

          -  No known or suspected hypersensitivity to interferon alfa or to any excipient or
             vehicle included in the formulation or delivery system

          -  No history of autoimmune disease

          -  No autoimmune hepatitis

          -  No immunosuppressed transplantation recipients

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use 2 effective methods of contraception 4 weeks before, during,
             and for 4 weeks after study participation

          -  No pre-existing thyroid abnormalities for which thyroid function cannot be maintained
             in the normal range

          -  No severe psychiatric condition or disorder, including suicidal ideation or attempt

          -  No other active malignancy except nonmelanoma skin cancer

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No prior immunotherapy

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  See Disease Characteristics

          -  More than 4 weeks since prior radiotherapy

        Surgery

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uzair B. Chaudhary, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gustavo Leone</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of South Carolina, Hollings Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hollings Cancer Center at Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>September 7, 2004</study_first_submitted>
  <study_first_submitted_qc>September 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2004</study_first_posted>
  <results_first_submitted>May 4, 2018</results_first_submitted>
  <results_first_submitted_qc>June 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 12, 2018</results_first_posted>
  <last_update_submitted>June 13, 2018</last_update_submitted>
  <last_update_submitted_qc>June 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PEG-Intron, BM-CSF and Thalidomide</title>
          <description>PEG-interferon alfa-2b: Peg-Intron 1ug/kg Subcutaneous on day 1 and day 8 of each cycle. Each cycle is 21 days.
GM-CSF: GM-CSF 250 ug/m2 subcutaneously daily from days 1-10 or each 21 day Peg-Intron cycle
thalidomide: 200mg daily by mouth</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PEG-Intron, BM-CSF and Thalidomide</title>
          <description>PEG-interferon alfa-2b: Peg-Intron 1ug/kg Subcutaneous on day 1 and day 8 of each cycle. Each cycle is 21 days.
GM-CSF: GM-CSF 250 ug/m2 subcutaneously daily from days 1-10 or each 21 day Peg-Intron cycle
thalidomide: 200mg daily by mouth</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate</title>
        <description>To define the response rate in metastatic renal cell carcinoma patients receiving Peg-Intron, GM-CSF and thalidomide</description>
        <time_frame>while on study, every 4 cycles; while off study, every 3 months for 1 year, then every 6 month for 2 years, then every year</time_frame>
        <population>Data for this endpoint was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>PEG-Intron, BM-CSF and Thalidomide</title>
            <description>PEG-interferon alfa-2b: Peg-Intron 1ug/kg Subcutaneous on day 1 and day 8 of each cycle. Each cycle is 21 days.
GM-CSF: GM-CSF 250 ug/m2 subcutaneously daily from days 1-10 or each 21 day Peg-Intron cycle
thalidomide: 200mg daily by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>To define the response rate in metastatic renal cell carcinoma patients receiving Peg-Intron, GM-CSF and thalidomide</description>
          <population>Data for this endpoint was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <time_frame>time from registration to the time of progressive disease among patients who achieve at least a partial response to treatment.</time_frame>
        <population>Data for this endpoint was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>PEG-Intron, BM-CSF and Thalidomide</title>
            <description>PEG-interferon alfa-2b: Peg-Intron 1ug/kg Subcutaneous on day 1 and day 8 of each cycle. Each cycle is 21 days.
GM-CSF: GM-CSF 250 ug/m2 subcutaneously daily from days 1-10 or each 21 day Peg-Intron cycle
thalidomide: 200mg daily by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <population>Data for this endpoint was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Adverse Events Assessed by NCI CTC Version 2</title>
        <time_frame>From the first day of treatment until the end of treatment visit, an average of 6 months</time_frame>
        <population>Data for this endpoint was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>PEG-Intron, BM-CSF and Thalidomide</title>
            <description>PEG-interferon alfa-2b: Peg-Intron 1ug/kg Subcutaneous on day 1 and day 8 of each cycle. Each cycle is 21 days.
GM-CSF: GM-CSF 250 ug/m2 subcutaneously daily from days 1-10 or each 21 day Peg-Intron cycle
thalidomide: 200mg daily by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Adverse Events Assessed by NCI CTC Version 2</title>
          <population>Data for this endpoint was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <time_frame>From registration until diease progression or death, whichever comes first.</time_frame>
        <population>Data for this endpoint was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>PEG-Intron, BM-CSF and Thalidomide</title>
            <description>PEG-interferon alfa-2b: Peg-Intron 1ug/kg Subcutaneous on day 1 and day 8 of each cycle. Each cycle is 21 days.
GM-CSF: GM-CSF 250 ug/m2 subcutaneously daily from days 1-10 or each 21 day Peg-Intron cycle
thalidomide: 200mg daily by mouth</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <population>Data for this endpoint was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From day 1 of study treatment until end of study, for an average of 6 months</time_frame>
      <desc>Data for this endpoint was not collected</desc>
      <group_list>
        <group group_id="E1">
          <title>PEG-Intron, BM-CSF and Thalidomide</title>
          <description>PEG-interferon alfa-2b: Peg-Intron 1ug/kg Subcutaneous on day 1 and day 8 of each cycle. Each cycle is 21 days.
GM-CSF: GM-CSF 250 ug/m2 subcutaneously daily from days 1-10 or each 21 day Peg-Intron cycle
thalidomide: 200mg daily by mouth</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kate Anderton</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-2708</phone>
      <email>anderton@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

